Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: A consensus of the italian association of medical oncology and the Italian society of pathology and cytopathology

Antonio Marchetti, Andrea Ardizzoni, Mauro Papotti, Lucio Crinò, Giulio Rossi, Cesare Gridelli, Massimo Barberis, Eugenio Maiorano, Nicola Normanno, Gian Luigi Taddei, Giorgio Scagliotti, Claudio Clemente, Carmine Pinto

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

INTRODUCTION: Recent clinical trials led to the approval of crizotinib (PF-02341066; Pfizer) by the U.S. Food and Drug Administration for the treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients whose tumors are positive for anaplastic lymphoma kinase (ALK) alterations. The European Medicines Agency accepted the regulatory submission of crizotinib for the treatment of these patients. Therefore, ALK gene testing has become mandatory to choose the most appropriate therapy. METHODS: To help physicians, involved in the management of NSCLC patients to be treated with ALK inhibitors in Italy, the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology identified a large panel of Italian medical oncologists and pathologists that outlined recommendations for ALK testing in NSCLC patients. RESULTS: The guidelines produced include specific information on the target patient population, the biological material for molecular analysis, a section dedicated to the histocytopathologic diagnosis of NSCLC, and the methods for the assessment of ALK alterations that are summarized in this article. CONCLUSIONS: Clinicopathologic recommendations were produced to guide the management of NSCLC patients who need to be tested for ALK rearrangements before treatment with ALK inhibitors.

Original languageEnglish
Pages (from-to)352-358
Number of pages7
JournalJournal of Thoracic Oncology
Volume8
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Medical Oncology
Gene Rearrangement
Non-Small Cell Lung Carcinoma
Pathology
Health Services Needs and Demand
United States Food and Drug Administration
Therapeutics
anaplastic lymphoma kinase
Italy
Clinical Trials
Guidelines
Physicians
Genes
crizotinib
Neoplasms

Keywords

  • Anaplastic lymphoma kinase gene rearrangements
  • Guidelines
  • Non-small-cell lung cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer : A consensus of the italian association of medical oncology and the Italian society of pathology and cytopathology. / Marchetti, Antonio; Ardizzoni, Andrea; Papotti, Mauro; Crinò, Lucio; Rossi, Giulio; Gridelli, Cesare; Barberis, Massimo; Maiorano, Eugenio; Normanno, Nicola; Taddei, Gian Luigi; Scagliotti, Giorgio; Clemente, Claudio; Pinto, Carmine.

In: Journal of Thoracic Oncology, Vol. 8, No. 3, 03.2013, p. 352-358.

Research output: Contribution to journalArticle

Marchetti, Antonio ; Ardizzoni, Andrea ; Papotti, Mauro ; Crinò, Lucio ; Rossi, Giulio ; Gridelli, Cesare ; Barberis, Massimo ; Maiorano, Eugenio ; Normanno, Nicola ; Taddei, Gian Luigi ; Scagliotti, Giorgio ; Clemente, Claudio ; Pinto, Carmine. / Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer : A consensus of the italian association of medical oncology and the Italian society of pathology and cytopathology. In: Journal of Thoracic Oncology. 2013 ; Vol. 8, No. 3. pp. 352-358.
@article{9e92fb5fe998410fb734dc7993e3b642,
title = "Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: A consensus of the italian association of medical oncology and the Italian society of pathology and cytopathology",
abstract = "INTRODUCTION: Recent clinical trials led to the approval of crizotinib (PF-02341066; Pfizer) by the U.S. Food and Drug Administration for the treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients whose tumors are positive for anaplastic lymphoma kinase (ALK) alterations. The European Medicines Agency accepted the regulatory submission of crizotinib for the treatment of these patients. Therefore, ALK gene testing has become mandatory to choose the most appropriate therapy. METHODS: To help physicians, involved in the management of NSCLC patients to be treated with ALK inhibitors in Italy, the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology identified a large panel of Italian medical oncologists and pathologists that outlined recommendations for ALK testing in NSCLC patients. RESULTS: The guidelines produced include specific information on the target patient population, the biological material for molecular analysis, a section dedicated to the histocytopathologic diagnosis of NSCLC, and the methods for the assessment of ALK alterations that are summarized in this article. CONCLUSIONS: Clinicopathologic recommendations were produced to guide the management of NSCLC patients who need to be tested for ALK rearrangements before treatment with ALK inhibitors.",
keywords = "Anaplastic lymphoma kinase gene rearrangements, Guidelines, Non-small-cell lung cancer, Targeted therapy",
author = "Antonio Marchetti and Andrea Ardizzoni and Mauro Papotti and Lucio Crin{\`o} and Giulio Rossi and Cesare Gridelli and Massimo Barberis and Eugenio Maiorano and Nicola Normanno and Taddei, {Gian Luigi} and Giorgio Scagliotti and Claudio Clemente and Carmine Pinto",
year = "2013",
month = "3",
doi = "10.1097/JTO.0b013e31827d5280",
language = "English",
volume = "8",
pages = "352--358",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer

T2 - A consensus of the italian association of medical oncology and the Italian society of pathology and cytopathology

AU - Marchetti, Antonio

AU - Ardizzoni, Andrea

AU - Papotti, Mauro

AU - Crinò, Lucio

AU - Rossi, Giulio

AU - Gridelli, Cesare

AU - Barberis, Massimo

AU - Maiorano, Eugenio

AU - Normanno, Nicola

AU - Taddei, Gian Luigi

AU - Scagliotti, Giorgio

AU - Clemente, Claudio

AU - Pinto, Carmine

PY - 2013/3

Y1 - 2013/3

N2 - INTRODUCTION: Recent clinical trials led to the approval of crizotinib (PF-02341066; Pfizer) by the U.S. Food and Drug Administration for the treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients whose tumors are positive for anaplastic lymphoma kinase (ALK) alterations. The European Medicines Agency accepted the regulatory submission of crizotinib for the treatment of these patients. Therefore, ALK gene testing has become mandatory to choose the most appropriate therapy. METHODS: To help physicians, involved in the management of NSCLC patients to be treated with ALK inhibitors in Italy, the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology identified a large panel of Italian medical oncologists and pathologists that outlined recommendations for ALK testing in NSCLC patients. RESULTS: The guidelines produced include specific information on the target patient population, the biological material for molecular analysis, a section dedicated to the histocytopathologic diagnosis of NSCLC, and the methods for the assessment of ALK alterations that are summarized in this article. CONCLUSIONS: Clinicopathologic recommendations were produced to guide the management of NSCLC patients who need to be tested for ALK rearrangements before treatment with ALK inhibitors.

AB - INTRODUCTION: Recent clinical trials led to the approval of crizotinib (PF-02341066; Pfizer) by the U.S. Food and Drug Administration for the treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients whose tumors are positive for anaplastic lymphoma kinase (ALK) alterations. The European Medicines Agency accepted the regulatory submission of crizotinib for the treatment of these patients. Therefore, ALK gene testing has become mandatory to choose the most appropriate therapy. METHODS: To help physicians, involved in the management of NSCLC patients to be treated with ALK inhibitors in Italy, the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology identified a large panel of Italian medical oncologists and pathologists that outlined recommendations for ALK testing in NSCLC patients. RESULTS: The guidelines produced include specific information on the target patient population, the biological material for molecular analysis, a section dedicated to the histocytopathologic diagnosis of NSCLC, and the methods for the assessment of ALK alterations that are summarized in this article. CONCLUSIONS: Clinicopathologic recommendations were produced to guide the management of NSCLC patients who need to be tested for ALK rearrangements before treatment with ALK inhibitors.

KW - Anaplastic lymphoma kinase gene rearrangements

KW - Guidelines

KW - Non-small-cell lung cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84874104032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874104032&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e31827d5280

DO - 10.1097/JTO.0b013e31827d5280

M3 - Article

C2 - 23407559

AN - SCOPUS:84874104032

VL - 8

SP - 352

EP - 358

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 3

ER -